Anti-Infective Drugs Market By Type (Anti-Bacterials, Anti-Virals, Anti-Fungals, Others), By Range (Broad Spectrum, Narrow Spectrum) - Growth, Share, Opportunities & Competitive Analysis, 2018 – 2026

Industry Outlook

The growing prevalence of infections such as influenza, the ebola virus, and HIV has brought significant changes in the outlook of the general population about infections and their management, and consequently, in the consumption of anti-infective agents. Furthermore, collaborative efforts from organizations such as the WHO and health ministries to raise awareness and improve treatment outcomes for communicable diseases are important factors influencing the growth of the anti-infectives market. Additionally, the introduction of novel therapeutic agents, extensive R&D initiatives, and swift commercialization of pipeline products will also contribute to market growth. The global anti-infective drugs market is expected to reach US$ 168,628.1 Mn by 2026, expanding at a CAGR of 4.3/5 from 2018 to 2026.

Market Synopsis

Higher Prevalence of Bacterial Infections to Contribute to the Dominance of Antibacterial Drugs

The antibacterial segment is the largest revenue contributor to the global anti-infective drugs market. High incidences of bacterial infections, high prescription rates, and greater adoption of broad-spectrum antibiotics mainly drive the dominance of this segment. Antifungals such as azoles, polyenes, and echinocandins are in high demand due to their proven ability to treat systemic fungal infections. Furthermore, the anti-viral drugs segment will register the fastest growth during the forecast period from 2018 to 2026 due to the swift introduction of novel drugs and the ever-growing prevalence of viral infections worldwide that demand prolonged administration of anti-virals. The discovery of newer forms of viral agents and growing collaborations between governments, research organizations, and drug manufacturers also support the swift growth of this segment.

Broad-Spectrum Anti-Infectives to Spearhead the Global Market

The growing incidence of drug-resistant bacterial infections is a prime aspect governing the demand for broad-spectrum anti-infectives. Broad-spectrum antibiotics act on both gram-positive and gram-negative pathogens, therefore expanding the range of treatment. This feature of broad-spectrum antibiotics makes them ideal in cases of drug resistance and infection with multiple bacteria. On the other hand, the demand for narrow-spectrum anti-infective drugs will be steady and limited to such infections where the identity of the causative pathogen is known.

High Burden of Hepatitis, HIV, and Tuberculosis to Direct the Market's Growth

The Global Burden of Disease report released in 2017 stated that the number of deaths caused by viral hepatitis had surpassed all chronic infections, including HIV and AIDS, tuberculosis, and malaria. The study reported that in 2016, the total deaths caused by hepatitis, including cirrhosis, hepatitis A, B, C, D, and E, and liver cancer accounted for 1.34 million, which exceeded tuberculosis at 1.2 million and HIV/AIDS and malaria at 1 million and 719,000 deaths, respectively. The increasing incidence and reporting of hepatitis with the help of advanced diagnostic techniques mainly contribute to the growing demand for anti-infectives for the treatment of these diseases.

The Asia Pacific region is poised to become a lucrative market for anti-infectives.

The market for anti-infective drugs is dominated by North America in terms of revenue and volume consumption. The prominence of the North American market is driven by the presence of sophisticated and well-organized healthcare infrastructure, as well as the increased adoption of advanced and novel medications. Because of its large geriatric population and the rapid introduction and adoption of novel therapeutics in the region, the United States is the leading stakeholder in the global market. Favorable reimbursements also play a critical role in assisting the dominance of the U.S. market. Asia Pacific, on the grounds of an escalating patient pool and rapid improvements in the healthcare system, will be the fastest-progressing regional market during the forecast period.

Periods of History and Forecast

2016 : Historic year.

2017: Base Year

2018–2026: Forecast Period

This research report presents the analysis of each considered segment for the period from 2016 to 2026, using 2017 as the base year for estimations. Compounded annual growth rates (CAGRs) for each segment are calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

The anti-infective drugs market report provides a quantitative assessment of the industry terms of current and forecasted market size while also presenting the market dynamics. This market is segmented based on drugs, type of infection, range of action, and geography.

By Drugs (2016–2026; US$ Mn)

  • Antibacterial
  • Anti-virals
  • Anti-fungals
  • Others (Antihelmethics, Antiprotozoals, etc.)

By Range (2016–2026; US$ Mn)

  • Broad Spectrum
  • Narrow Spectrum

By Range (2016–2026; US$ Mn)

  • Hepatitis B
  • Hepatitis C
  • HIV
  • Malaria
  • Tuberculosis
  • Urinary Tract Infection
  • Others (meningitis, pneumonia, sexually transmitted diseases, etc.)

Geography Segment (2016–2026; US$ Mn)

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific (APAC)
    • China
    • Japan
    • India
    • Rest of APAC
  • Latin America (LATAM)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • GCC
    • Rest of the Middle East and Africa

The ongoing dynamics in the global anti-infective drugs market are scrutinized in this study to understand the progress of this market. The market dynamics are assessed in terms of drivers, challenges, and opportunities, thus giving insights into the positive aspects and pain points prevalent in the market. Prominent players in this market are also analyzed in terms of business overview, financial status, product portfolio, and key developments. The major companies engaged in the global anti-infective drugs market include Abbott Laboratories, Inc., Allergen plc, Astellas Pharma Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co., Boehringer Ingelheim, F. Hoffman-La Roche Ltd., Gilead Sciences, GlaxoSmithKline Plc, Johnson and Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi-Aventis SA, and Novartis AG.

Frequently Asked Questions:

The market for Anti-Infective Drugs is expected to reach US$ XX Bn in 2026.

The Anti-Infective Drugs market is expected to see significant CAGR growth over the coming years,at XX%.

The report is forecasted from 2018-2026.

The base year of this report is 2017.

Abbott Laboratories Inc.,Allergen plc,Astellas Pharma Inc.,AstraZeneca Plc,Bayer AG are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  Aug 2018
Category:  Pharmaceuticals
Report ID:   59244
Report Format:   PDF
Pages:   120
Rating:    4.1 (40)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support